BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 33940164)

  • 1. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
    Jangampalli Adi P; Reddy PH
    Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
    Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
    Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.
    Pradeepkiran JA; Reddy AP; Reddy PH
    Drug Discov Today; 2019 Feb; 24(2):616-623. PubMed ID: 30453058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
    Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
    Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
    Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why Microtubules Should Be Considered as One of the Supplementary Targets for Designing Neurotherapeutics.
    Das G; Ghosh S
    ACS Chem Neurosci; 2019 Mar; 10(3):1118-1120. PubMed ID: 30657675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
    Brunden KR; Trojanowski JQ; Lee VM
    Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
    Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
    Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
    Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
    J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
    Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
    Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rho-kinase ROCK inhibitors reduce oligomeric tau protein.
    Hamano T; Shirafuji N; Yen SH; Yoshida H; Kanaan NM; Hayashi K; Ikawa M; Yamamura O; Fujita Y; Kuriyama M; Nakamoto Y
    Neurobiol Aging; 2020 May; 89():41-54. PubMed ID: 31982202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models.
    Wang W; Zhou Q; Jiang T; Li S; Ye J; Zheng J; Wang X; Liu Y; Deng M; Ke D; Wang Q; Wang Y; Wang JZ
    Theranostics; 2021; 11(11):5279-5295. PubMed ID: 33859747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.
    Quraishe S; Cowan CM; Mudher A
    Mol Psychiatry; 2013 Jul; 18(7):834-42. PubMed ID: 23587881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.
    Moore KBE; Hung TJ; Fortin JS
    Drug Discov Today; 2023 Mar; 28(3):103487. PubMed ID: 36634842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of tau-induced neurodegeneration.
    Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
    Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tau in Alzheimer's disease and related disorders.
    Medeiros R; Baglietto-Vargas D; LaFerla FM
    CNS Neurosci Ther; 2011 Oct; 17(5):514-24. PubMed ID: 20553310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.